Related Experiment Video
Updated: Aug 6, 2026
14:24
Percutaneous Contrast Echocardiography-guided Intramyocardial Injection and Cell Delivery in a Large Preclinical Model
Published on: January 21, 2018
Nesiritide: a unique therapeutic cardiac peptide
1University of Alabama at Birmingham, Birmingham, AL, USA.
Reviews in Cardiovascular Medicine
|November 20, 2002
Summary
Nesiritide, a recombinant human B-type natriuretic peptide, offers a new treatment for heart failure. It provides safe and effective hemodynamic improvements, including vasodilation and natriuresis, for managing decompensated congestive heart failure.
Area of Science:
- Cardiology
- Pharmacology
- Biochemistry
Background:
- Congestive heart failure (CHF) is a complex condition requiring novel therapeutic agents.
- Nesiritide is a recombinant form of human B-type natriuretic peptide (BNP).
- BNP plays a crucial role in cardiovascular homeostasis.
Purpose of the Study:
- To review the physiology and pathophysiology of natriuretic peptides.
- To evaluate the clinical data, hemodynamic effects, efficacy, and safety of nesiritide in heart failure treatment.
Main Methods:
- Review of existing literature on natriuretic peptides and nesiritide.
- Analysis of clinical trial data regarding nesiritide's impact on heart failure patients.
- Critique of hemodynamic effects, efficacy, and safety profiles.
Main Results:
- Nesiritide exhibits balanced arterial and venous vasodilatation.
- The drug promotes significant natriuresis and diuresis.
- Clinical data suggests nesiritide is a safe and effective option for heart failure management.
Conclusions:
- Nesiritide represents a novel therapeutic peptide class for heart failure.
- It offers unique and safe hemodynamic properties for managing decompensated CHF.
- Nesiritide shows promise as an important agent in cardiovascular pharmacotherapy.
Related Concept Videos
01:27Transducer Mechanism: Enzyme-Linked Receptors
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
01:30Adrenergic Agonists: Therapeutic Uses
Adrenergic agonists have diverse therapeutic uses across various medical conditions and emergencies.
Emergency and Intensive Care Unit (ICU) applications: Pressor agents increase blood pressure, heart rate, and contractility in shock and organ failure situations. Dopamine can induce vasodilation and stimulate adrenoceptors. Endogenous catecholamines are effective in treating cardiogenic shock. α2-agonists like clonidine can reverse anesthesia-induced hypertension.
Allergies and anaphylaxis:...
Emergency and Intensive Care Unit (ICU) applications: Pressor agents increase blood pressure, heart rate, and contractility in shock and organ failure situations. Dopamine can induce vasodilation and stimulate adrenoceptors. Endogenous catecholamines are effective in treating cardiogenic shock. α2-agonists like clonidine can reverse anesthesia-induced hypertension.
Allergies and anaphylaxis:...
01:26Heart Failure Drugs: Inotropic Agents
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
01:25Cardiopulmonary Resuscitation IV: Pharmacological Management
Pharmacologic intervention is crucial in treating cardiac arrest patients during ACLS or Advanced Cardiovascular Life Support. The ACLS algorithms guide the administration of specific drugs based on the patient's cardiac arrest rhythm, which includes pulseless ventricular tachycardia (VT), ventricular fibrillation (VF), asystole, and pulseless electrical activity (PEA).EpinephrineIndication: Epinephrine is the first-line drug for all cardiac arrest rhythms.Mechanism of Action: Epinephrine...